$CW

Bamford Lynn M sold $1.8M of CW

Bamford Lynn M (Chair and CEO) sold 2,500 shares of CURTISS WRIGHT CORP (CW) at $721.72 ($1.80M total) on 2026-06-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bamford Lynn M
Published Jun 10, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CW
Neutral
medium confidence
Mentioned
$CW
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CWNeutralLow
01

Why it matters

The newest disclosed fact is the CEO/Chair’s open-market sale amount and execution date; it may marginally affect sentiment but does not introduce new company fundamentals.

02

Market read

Insider selling under 10b5-1 is typically a low-signal event; any trading impact is likely limited and short-lived.

03

What to watch

Traders may over-weight insider sales; without accompanying buys, guidance changes, or operational news, the signal-to-noise is low.

Relevance 5/10Novelty 8/10Timing: Filed 2026-06-10; sale executed 2026-06-09

Background

The article is an SEC Form 4 insider transaction disclosure for Curtiss-Wright (CW).

Company-level read

Ticker impact

$CWNeutralMedium confidence
Context

Curtiss-Wright CEO/Chair Bamford Lynn M sold 2,500 shares for ~$1.80M via an open-market transaction under a 10b5-1 plan.

Expected impact

Low near-term impact; any effect is likely limited to sentiment/positioning rather than fundamentals.

Evidence & confidence

The filing is a routine Form 4 insider sale with a pre-arranged 10b5-1 plan; it signals liquidity/portfolio management more than a new negative thesis.

Market effects

Minimal; this is company-specific insider liquidity rather than a sector/regulatory signal.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may be mechanically scheduled and not informative about near-term outlook.

Key entities

  • Curtiss-Wright Corp

    Subject of the SEC Form 4 insider transaction disclosure.

  • Bamford Lynn M

    Chair and CEO who sold 2,500 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CWMedAI 8/10

Why is Curtiss-Wright stock sliding today?

Curtiss-Wright stock fell 4.0% after announcing CEO Lynn M. Bamford will transition to Executive Chair, with COO Kevin M. Rayment succeeding in 2027. The change introduced strategic uncertainty, and the stock is near a 52-week low of $544.64, below its high of $808.16. The ex-dividend date is also approaching, adding to the pressure.

$CWMed

CW Initiated Coverage by Guggenheim -- Rating Upgraded to Buy

Guggenheim initiated coverage on Curtiss-Wright (CW) with a 'Buy' rating and a $786.00 price target. The stock is currently trading at $551.21, which is 24.3% above its GF Value™ of $443.58, indicating overvaluation. CW has a GF Score™ of 94/100, reflecting strong performance in growth and profitability, but a valuation rank of 5/10. Insider activity shows net selling of $705,928 over the last three months.

$CWMed

Curtiss Wright (CW) Wins New Defense Work, Is The Stock Cheap After The Selloff?

Curtiss-Wright (CW) secured $40M in contracts for the U.S. Army's air defense system. Its stock is down 24.3% over 30 days, but up 17.8% over 1 year. Analysts debate its valuation, with some seeing it as undervalued at $566.75, citing strong backlog growth and growth projections. The company trades at a P/E of 38.7x, lower than peers but higher than its own fair ratio of 24.8x.

$CWMed

Piper Sandler initiates Curtiss-Wright stock at neutral on valuation

Piper Sandler initiated coverage on Curtiss-Wright (NYSE:CW) with a Neutral rating and $665 price target, citing valuation concerns. The company reported Q2 earnings beating EPS estimates but missing on revenue. Curtiss-Wright's order book is up 12% YTD, and it raised its full-year outlook. Piper Sandler notes the stock's multiple expansion and potential overvaluation.

$CWHighAI 8/10

Curtiss-Wright reports strong Q2 2026 results and raises full-year guidance across defense, nuclear and industrial markets

Curtiss-Wright reported Q2 2026 sales of $924M, adjusted EPS of $3.72, and adjusted operating margin of 19.4%, all above expectations. The company raised full-year guidance to 8-9% sales growth and 14-16% EPS growth, with free cash flow outlook at $585M-$605M. New orders increased 8% YoY to $1.1B, and backlog reached $4.5B, up 10% from year-end 2025.